However, when observational (mostly retrospective) studies compared clinical outcomes in DPP4 inhibitor users vs. non-users among diabetes patients with COVID-19, the overall results regarding the risk of progression towards more severe forms of disease and mortality were heterogenous. Here, DPP4 is linked to COVID-19.